Stem cell researchers gain on U.S. court decision

ValBrickates Kennedy

BOSTON (MarketWatch) -- Shares of several stem cell research groups were on a roll early Monday in the wake of a U.S. appeals court decision that will allow researchers who experiment with human embryonic stem cells to apply for federal funding through the National Institutes of Health. StemCells Inc.
STEM, +1.28%
was the the lead advancer, with shares rallying 12% to 94 cents, followed by Advanced Cell Technology
actc
up 9%. Also gaining were Pluristem Therapeutics
PSTI, +0.84%
Geron Corp.
GERN, -1.94%
and Aastrom Biosciences
astm, +0.00%

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.